CHISON MEDICAL(SH:688358) Zheng Quan Zhi Xing·2025-08-29 22:41Financial Performance - The company reported total revenue of 236 million yuan for the first half of 2025, a decrease of 4.61% year-on-year [1] - The net profit attributable to shareholders was 69.696 million yuan, down 14.32% compared to the previous year [1] - In Q2 2025, total revenue was 108 million yuan, showing a slight increase of 1.37% year-on-year, while net profit for the same quarter was 28.0818 million yuan, a decline of 21.57% [1] Key Financial Ratios - The gross margin was 60.65%, an increase of 0.93% year-on-year, while the net margin decreased by 10.18% to 29.51% [1] - The total of selling, administrative, and financial expenses reached 30.1444 million yuan, accounting for 12.76% of revenue, which is an increase of 28.3% year-on-year [1] - Earnings per share (EPS) decreased by 15.07% to 0.62 yuan, while the net asset per share increased by 1.18% to 12.29 yuan [1] Accounts Receivable and Cash Flow - The accounts receivable amounted to 184 million yuan, representing a 4.33% increase year-on-year, and accounted for 130.71% of the net profit [1][3] - Operating cash flow per share remained stable at 0.48 yuan, with a slight decrease of 1.03% year-on-year [1] Investment Insights - The company's return on invested capital (ROIC) was 7.82% last year, indicating average capital returns, with a historical median ROIC of 9.47% since its listing [3] - The company has a healthy cash asset position, which is favorable for its debt repayment capabilities [3] Fund Holdings - The largest fund holding in the company is the Xingyin Xinghui One-Year Holding Mixed A Fund, with 171,700 shares, showing an increase in holdings [4] - Other funds have shown mixed changes in their positions, with some increasing and others decreasing their holdings in the company [4]